Related references
Note: Only part of the references are listed.Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
Naoya Kitamura et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Postoperative Management of Salivary Gland Tumors
Nikhil P. Joshi et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
Daniel J. Klionsky et al.
AUTOPHAGY (2021)
In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101
Laura Masuelli et al.
INVESTIGATIONAL NEW DRUGS (2020)
Apoptosis signaling molecules as treatment targets in head and neck squamous cell carcinoma
Thomas J. Ow et al.
LARYNGOSCOPE (2020)
Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine
Sara S. Bashraheel et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials
Choudhary Harsha et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Curcumin Enhances the Antitumoral Effect Induced by the Recombinant Vaccinia Neu Vaccine (rV-neuT) in Mice with Transplanted Salivary Gland Carcinoma Cells
Chiara Focaccetti et al.
NUTRIENTS (2020)
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges
G. R. Tundo et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease
Larissa Di Villeneuve et al.
FRONTIERS IN ONCOLOGY (2020)
Pharmacological Inhibition of ATR Can Block Autophagy through an ATR-Independent Mechanism
Elizabeth Bowler et al.
ISCIENCE (2020)
Head and Neck Cancer
Laura Q. M. Chow
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clinical update on head and neck cancer: molecular biology and ongoing challenges
Elham Alsahafi et al.
CELL DEATH & DISEASE (2019)
Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer
Hyung Kwon Byeon et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2019)
The insulin-degrading enzyme is an allosteric modulator of the 20S proteasome and a potential competitor of the 19S
Diego Sbardella et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2018)
Molecular targeted therapy: Treating cancer with specificity
Yeuan Ting Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Wnt3a Neutralization Enhances T-cell Responses through Indirect Mechanisms and Restrains Tumor Growth
Ilenia Pacella et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Electrochemically Reduced Water Delays Mammary Tumors Growth in Mice and Inhibits Breast Cancer Cells Survival In Vitro
Giovanni Vanni Frajese et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2018)
Effect of the BH3 Mimetic Polyphenol (-)-Gossypol (AT-101) on the in vitro and in vivo Growth of Malignant Mesothelioma
Monica Benvenuto et al.
FRONTIERS IN PHARMACOLOGY (2018)
Role of Akt Isoforms Controlling Cancer Stem Cell Survival, Phenotype and Self-Renewal
Sergio Rivas et al.
BIOMEDICINES (2018)
Positioning of proteasome inhibitors in therapy of solid malignancies
Margot S. F. Roeten et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line
Laura Masuelli et al.
ONCOTARGET (2017)
In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma
Laura Masuelli et al.
FRONTIERS IN PHARMACOLOGY (2017)
Chloroquine supplementation increases the cytotoxic effect of curcumin against Her2/neu overexpressing breast cancer cells in vitro and in vivo in nude mice while counteracts it in immune competent mice
L. Masuelli et al.
ONCOIMMUNOLOGY (2017)
Leucovorin Enhances the Anticancer Effect of Bortezomib in Colorectal Cancer Cells
Shu Wang et al.
SCIENTIFIC REPORTS (2017)
The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death
Ido Livneh et al.
CELL RESEARCH (2016)
Inhibition of Proteasome Activity Induces Formation of Alternative Proteasome Complexes
Vanessa Welk et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing Autophagy
Insoon Chang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Degradation of oxidized proteins by the proteasome: Distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways
Rachel Raynes et al.
MOLECULAR ASPECTS OF MEDICINE (2016)
In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors
Monica Benvenuto et al.
ONCOTARGET (2016)
Natural humoral immune response to ribosomal P0 protein in colorectal cancer patients
Monica Benvenuto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome
Peter Tsvetkov et al.
ELIFE (2015)
Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism
J. Bullenkamp et al.
CELL DEATH & DISEASE (2014)
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation
C. Kao et al.
CELL DEATH & DISEASE (2014)
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab
Gerald S. Falchook et al.
ONCOTARGET (2014)
Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas
Laura Masuelli et al.
ONCOTARGET (2014)
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest
Changyou Li et al.
CELL CYCLE (2013)
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group
Jill Gilbert et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2013)
Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation
Changyou Li et al.
CANCER LETTERS (2012)
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Alexei F. Kisselev et al.
CHEMISTRY & BIOLOGY (2012)
Management of salivary gland tumors
Guy Andry et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1
Yong Sang Hong et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Phase I Trial Using the Proteasome Inhibitor Bortezomib and Concurrent Chemoradiotherapy for Head-and-Neck Malignancies
Gregory J. Kubicek et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells
Yu-Chin Lin et al.
ORAL ONCOLOGY (2012)
Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN
Martin Leinung et al.
ONCOLOGY LETTERS (2012)
A Phase 2 Trial of Bortezomib Followed by the Addition of Doxorubicin at Progression in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck A Trial of the Eastern Cooperative Oncology Group (E1303)
Athanassios Argiris et al.
CANCER (2011)
Oncogenic B-RAF Signaling in Melanoma Impairs the Therapeutic Advantage of Autophagy Inhibition
Jane L. Armstrong et al.
CLINICAL CANCER RESEARCH (2011)
Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
Athanassios Argiris et al.
CLINICAL CANCER RESEARCH (2011)
Novel Proteasome Inhibitors to Overcome Bortezomib Resistance
Amy M. Ruschak et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
C. H. Chung et al.
ANNALS OF ONCOLOGY (2010)
Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells
Sudharsan Periyasamy-Thandavan et al.
AUTOPHAGY (2010)
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines
Ying Wang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice
Laura Masuelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
From man to mouse and back again: advances in defining tumor AKTivities in vivo
David F. Restuccia et al.
DISEASE MODELS & MECHANISMS (2010)
PS-341 and Histone Deacetylase Inhibitor Synergistically Induce Apoptosis in Head and Neck Squamous Cell Carcinoma Cells
JinKoo Kim et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor
A. Z. Dudek et al.
BRITISH JOURNAL OF CANCER (2009)
Inhibition of Mek 1/2 kinase activity and stimulation of melanogenesis by 5,7-dimethoxycoumarin treatment of melanoma cells
Daniela Alesiani et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2009)
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death
Changyou Li et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL
Guangrong Lu et al.
CANCER BIOLOGY & THERAPY (2008)
Systemic therapies for recurrent and/or metastatic salivary gland cancers
Emanuela Vattemi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody
Anil Shanker et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway
Mercedes Lioni et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1 related mechanisms
Zhong Chen et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells
Changyou Li et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer
Angela M. Davies et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells:: the role of protein kinase Cδ
H. Yan et al.
LEUKEMIA (2007)
Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation
Charles N. Weber et al.
CANCER BIOLOGY & THERAPY (2007)
Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression
Tania Pannellini et al.
JOURNAL OF IMMUNOLOGY (2006)
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vanicha Vichai et al.
NATURE PROTOCOLS (2006)
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies
G Jackson et al.
CANCER TREATMENT REVIEWS (2005)
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
S Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Mario Boccadoro et al.
CANCER CELL INTERNATIONAL (2005)
Proteasome inhibitor PS-341, induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling
Y Yang et al.
CANCER SCIENCE (2004)
Phase II trial of bortezomib for patients with advanced renal cell carcinoma
GV Kondagunta et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Bortezomib as a potential treatment for prostate cancer
CN Papandreou et al.
CANCER RESEARCH (2004)
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: Implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma
KI Amiri et al.
CANCER RESEARCH (2004)
Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients
R Bei et al.
JOURNAL OF PATHOLOGY (2004)
Proteasome inhibitor PS-341 induces a apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells
A Fribley et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells
D Chauhan et al.
BLOOD (2004)
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
N Mitsiades et al.
BLOOD (2003)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
T Hideshima et al.
BLOOD (2003)
Proteasome inhibitors as new anticancer drugs
J Adams
CURRENT OPINION IN ONCOLOGY (2002)
Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma
R Bei et al.
JOURNAL OF PATHOLOGY (2001)
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
SA Shah et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2001)
DNA vaccination against rat Her-2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice
S Rovero et al.
JOURNAL OF IMMUNOLOGY (2000)
A gated channel into the proteasome core particle
M Groll et al.
NATURE STRUCTURAL BIOLOGY (2000)
Share Paper
